A hi-tech prostate cancer drug that offers hope to men who have run out of treatment options became available in the UK today.
Enzalutamide is licensed for patients with advanced prostate cancer who are no longer responding to hormone treatments or chemotherapy.
What to expect from the new drug:
- The new pill will cost around £2,500 a month.
- It can extend the lives of patients no longer being treated by almost five months.
- Seven out of 10 of the men in the Phase III Affirm trial taking enzalutamide were still alive after one year.
- It has a relative lack of side effects.
- The drug known as Xtandi, blocks molecular signals that allow the male hormone testosterone to fuel prostate cancer.
- It targets three different steps of the signalling pathway.
More top news
Paul Kohler was left needing facial reconstruction surgery for a fractured eye socket.
Imagine tucking into a mince pie on Christmas Day to find an insect staring back at you.
Victims as young as three were discovered on a secret stash of 1,100 images and video files hidden in Dr Lam Hoe Yeoh's home.